Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.

Lyman M, Lieuw V, Richardson R, Timmer A, Stewart C, Granger S, Woods R, Silacci M, Grabulovski D, Newman R.

J Biol Chem. 2018 Jun 15;293(24):9326-9334. doi: 10.1074/jbc.M117.818559. Epub 2018 Apr 20.

2.

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D.

MAbs. 2016;8(1):141-9. doi: 10.1080/19420862.2015.1093266. Epub 2015 Sep 22.

3.

Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.

Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D.

J Biol Chem. 2014 May 16;289(20):14392-8. doi: 10.1074/jbc.M113.534578. Epub 2014 Apr 1.

4.

Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo.

von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A, Lüscher TF, Neri D, Matter CM.

J Nucl Med. 2007 Apr;48(4):582-7.

5.

Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.

Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D.

Arthritis Res Ther. 2007;9(1):R9.

6.

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.

Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D.

Protein Eng Des Sel. 2006 Oct;19(10):471-8. Epub 2006 Aug 22.

7.

Recombinant antibodies for the depletion of abundant proteins from human serum.

Ettorre A, Rösli C, Silacci M, Brack S, McCombie G, Knochenmuss R, Elia G, Neri D.

Proteomics. 2006 Aug;6(16):4496-505.

PMID:
16858729
8.

Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, Neri D, Kosmehl H.

J Cancer Res Clin Oncol. 2006 Aug;132(8):537-46. Epub 2006 May 31.

PMID:
16788848
9.

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

Brack SS, Silacci M, Birchler M, Neri D.

Clin Cancer Res. 2006 May 15;12(10):3200-8.

10.

Design, construction, and characterization of a large synthetic human antibody phage display library.

Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, Viti F, Neri D.

Proteomics. 2005 Jun;5(9):2340-50.

PMID:
15880779
11.

Affinity-capture reagents for protein arrays.

Elia G, Silacci M, Scheurer S, Scheuermann J, Neri D.

Trends Biotechnol. 2002 Dec;20(12 Suppl):S19-22. Review.

PMID:
12570155

Supplemental Content

Loading ...
Support Center